855 3rd Avenue
Tel: 619-427-1300 x100
ProSciento is a full scope clinical R&D services provider, exclusively focused on diabetes, NASH and obesity. The company has completed more than 250 metabolic clinical projects, representing more early phase type 1 and type 2 diabetes clinical trials than any other U.S. provider.1 The team has supported the development of more than 15 metabolic drugs and devices on the market worldwide, and, in 2015, facilitated one of the year's largest early-stage licensing deals.
CEO: Marcus Hompesch
COO: Brian Mooney
CMO: Linda Morrow
CFO: Markus Hofmann
37 articles with ProSciento
High Point Clinical Trials Center Joins ProSciento's NASH PASS™ Initiative Focused on Accelerating NAFLD/NASH Clinical Trial Recruitment
HPCTC enters a multi-year partnership to establish a database enriched for subjects with NAFLD/NASH as a member of ProSciento's NASH PASS Site Network
Second Edition Textbook, 'Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease,' Provides Roadmap for Preclinical and Clinical Research
A timely analysis of different approaches to developing metabolic therapies, with insights from world-renowned experts in clinical drug development
ProSciento Forms NASH Roundtable, a Collaborative Forum of Leading Academic and Clinical Development Experts, to Advise Biopharma Drug Development Programs
ProSciento, Inc. announced today the formation of a NASH Roundtable, bringing together leading scientific and clinical development experts to advance science, methods and strategies for NASH clinical and pre-clinical research.
The FDA is often publishing draft guidelines and asking for expert feedback on that guidance. It’s been a busy week in this regard, with several areas of healthcare and drug development and manufacturing being covered by the agency. Here’s a look.
ProSciento, Inc. announced the appointment of Brian Mooney to the role of Chief Operating Officer (COO).
ProSciento Appoints Dr. Carine Beysen, Industry Expert in Stable Isotope Research, to Senior Scientific Team
ProSciento, Inc. announced the appointment of Dr. Carine Beysen as Senior Director of Clinical Research Innovation (CRI) Services.
Nieto joins ProSciento from the CRO PPD, where he served as Executive Director of Early Phase Business Development.
ProSciento And OWL Metabolomics Form Strategic Collaboration Focused On Accelerating NAFLD/NASH Clinical Trial Recruitment
ProSciento Appoints Dr. Kelvin Logan, Former Executive At INC Research And Quintiles, To Its Board Of Directors
Profil Institute for Clinical Research, Inc. Release: Research Institute Announces Corporate Name Change To ProSciento, Inc. To Reflect Expanded Metabolism-Focused Clinical R&D Services
Profil Institute for Clinical Research, Inc. And Antaros Medical Form Strategic Alliance To Incorporate Advanced Functional Imaging Techniques Into Cardiometabolic Clinical Research
Profil Institute for Clinical Research, Inc. And Shenzhen HighTide Biopharmaceutical Announce A Strategic Partnership Focused On The Development Of New Therapies For Diabetes And NAFLD/NASH
Profil Institute for Clinical Research, Inc. And LMC Diabetes Launch Strategic Partnership To Conduct Cross-Border Multi-Site Trials In Diabetes And Metabolism
Profil Institute for Clinical Research, Inc. And mySugr Collaborate To Advance Evidence-Based Clinical Validation Of Diabetes Mhealth Solutions
Profil Institute for Clinical Research, Inc. Appoints Dr. Christian Weyer As President And Chief Development Officer
Profil Institute for Clinical Research, Inc. Appoints Meryl Wiernik As Senior Director Of Clinical Operations
Profil Institute for Clinical Research, Inc. Unites Leading Experts In Biomarker Discovery And Clinical Research To Address The Medical Challenges Of NAFLD/NASH
Profil Institute for Clinical Research, Inc. Publishes White Paper Series Focused On The Current State Of Diabetes, Obesity And NAFLD/NASH Clinical Research And Development
Profil Institute for Clinical Research, Inc. Announces Metabolism Focused 'Discover & Translate' Partnership With Gubra
Profil Institute for Clinical Research, Inc. Expands Clinical Development Leadership Team With Prominent Industry Experts Drs. Michael Trautmann And Gordon Brandt